Who Eats the Other 35% of an NTAP Case?

CMS issued the FY 2027 inpatient final rule on July 31 with a headline every hospital finance office had already penciled in. 2.3%, built from a 3.2% market basket estimate less a 0.9 percentage point productivity adjustment, effective for discharges on or after October 1.

Underneath it is a number nobody budgeted against.

"Why does a quarter of next year's inpatient increase ride on product-specific codes?"

CMS-1849-F approves 19 technologies for new technology add-on payments in FY 2027: three through the traditional pathway, sixteen as FDA-designated Breakthrough Devices.

Forty-seven applications came in. Nineteen came out.

The agency priced each one, and the nineteen together come to $899.2 million.

One drug is $455.0 million of that (chart below).

Where The Money Actually Went

Total NTAP for FY 2027 lands at $1.74 billion. That splits into $840.5 million for technologies carried over from prior years, $417.7 million for the sixteen new devices, and $481.5 million for the three new drugs.

Year over year, CMS puts the increase at roughly $779 million. The same line moved $192 million last year.

The rule's impact appendix sizes the whole FY 2027 change at about $2.9 billion: $2.1 billion in operating, outlier and uncompensated care payments, $0.24 billion in capital, and $0.52 billion for everything else. That last bucket holds the add-on increase alongside the January 1, 2027 expiration of the Medicare-dependent hospital program and the temporary low-volume adjustment, which pull the other way.

Which means the add-on line by itself is bigger than the residual bucket it sits inside.

And unlike the 2.3%, none of it arrives on its own.